Literature DB >> 21289605

Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase.

Gregory T Collins1, Kathy A Carey, Diwahar Narasimhan, Joseph Nichols, Aaron A Berlin, Nicholas W Lukacs, Roger K Sunahara, James H Woods, Mei-Chuan Ko.   

Abstract

A long-acting mutant form of a naturally occurring bacterial cocaine esterase (T172R/G173Q CocE; double mutant CocE (DM CocE)) has previously been shown to antagonize the reinforcing, convulsant, and lethal effects of cocaine in rodents. However, the effectiveness and therapeutic characteristics of DM CocE in nonhuman primates, in a more clinically relevant context, are unknown. The current studies were aimed at (1) characterizing the cardiovascular effects of cocaine in freely moving rhesus monkeys, (2) evaluating the capacity of DM CocE to ameliorate these cocaine-induced cardiovascular effects when administered 10 min after cocaine, and (3) assessing the immunological responses of monkeys to DM CocE following repeated administration. Intravenous administration of cocaine produced dose-dependent increases in mean arterial pressure (MAP) and heart rate (HR) that persisted throughout the 2-h observation period following a dose of 3.2 mg/kg cocaine. Cocaine failed to produce reliable changes in electrocardiograph (ECG) parameters, body temperature, and locomotor activity. DM CocE produced a rapid and dose-dependent amelioration of the cardiovascular effects, with saline-like MAP measures restored within 5-10 min, and saline-like HR measures restored within 20-40 min of DM CocE administration. Although administration of DM CocE produced increases in anti-CocE antibodies, they did not appear to have a neutralizing effect on the capacity of DM CocE to reverse the cardiovascular effects of cocaine. In conclusion, these findings in monkeys provide strong evidence to suggest that highly efficient cocaine esterases, such as DM CocE, can provide a potential therapeutic option for treatment of acute cocaine intoxication in humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289605      PMCID: PMC3076304          DOI: 10.1038/npp.2010.242

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  46 in total

1.  Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED.

Authors:  K Blaho; B Logan; S Winbery; L Park; E Schwilke
Journal:  Am J Emerg Med       Date:  2000-09       Impact factor: 2.469

2.  Biochemical characterization and structural analysis of a highly proficient cocaine esterase.

Authors:  James M Turner; Nicholas A Larsen; Amrik Basran; Carlos F Barbas; Neil C Bruce; Ian A Wilson; Richard A Lerner
Journal:  Biochemistry       Date:  2002-10-15       Impact factor: 3.162

3.  Cocaine vaccines: antibody protection against relapse in a rat model.

Authors:  M R Carrera; J A Ashley; B Zhou; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

4.  Structural analysis of thermostabilizing mutations of cocaine esterase.

Authors:  Diwahar Narasimhan; Mark R Nance; Daquan Gao; Mei-Chuan Ko; Joanne Macdonald; Patricia Tamburi; Dan Yoon; Donald M Landry; James H Woods; Chang-Guo Zhan; John J G Tesmer; Roger K Sunahara
Journal:  Protein Eng Des Sel       Date:  2010-04-30       Impact factor: 1.650

5.  Crystal structure of a bacterial cocaine esterase.

Authors:  Nicholas A Larsen; James M Turner; James Stevens; Susan J Rosser; Amrik Basran; Richard A Lerner; Neil C Bruce; Ian A Wilson
Journal:  Nat Struct Biol       Date:  2002-01

6.  Cocaine: tolerance to its convulsant and cardiorespiratory stimulating effects in the monkey.

Authors:  M Matsuzaki; P J Spingler; A L Misra; S J Mule
Journal:  Life Sci       Date:  1976-07-15       Impact factor: 5.037

7.  Comparative effects of cocaine and pseudococaine on EEG activities, cardiorespiratory functions, and self-administration behavior in the rhesus monkey.

Authors:  M Matsuzaki; P J Spingler; E G Whitlock; A L Misra; S J Mulé
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

8.  Comparison of plasma cocaine levels during a "binge" pattern of cocaine administration in male and female rhesus monkeys.

Authors:  Nancy K Mello; Carrie A Bowen; Jack H Mendelson
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

9.  Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats.

Authors:  T J Baird; S X Deng; D W Landry; G Winger; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

10.  Pharmacokinetics of intravenous cocaine across the menstrual cycle in rhesus monkeys.

Authors:  Suzette M Evans; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

View more
  14 in total

1.  Repeated administration of a mutant cocaine esterase: effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys.

Authors:  Gregory T Collins; Remy L Brim; Kathleen R Noon; Diwahar Narasimhan; Nicholas W Lukacs; Roger K Sunahara; James H Woods; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-04-19       Impact factor: 4.030

Review 2.  Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction.

Authors:  Diwahar Narasimhan; James H Woods; Roger K Sunahara
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 3.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 4.  Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.

Authors:  Charles W Schindler; Steven R Goldberg
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 5.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

6.  Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?

Authors:  Fang Zheng; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

7.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

8.  Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats.

Authors:  Gregory T Collins; Matthew E Zaks; Alyssa R Cunningham; Carley St Clair; Joseph Nichols; Diwahar Narasimhan; Mei-Chuan Ko; Roger K Sunahara; James H Woods
Journal:  Drug Alcohol Depend       Date:  2011-04-11       Impact factor: 4.492

Review 9.  Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users.

Authors:  Stephen Brimijoin
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

10.  Evaluation of the hydrolytic activity of a long-acting mutant bacterial cocaine in the presence of commonly co-administered drugs.

Authors:  Remy L Brim; Kathleen R Noon; Joseph Nichols; Diwahar Narasimhan; James H Woods; Roger K Sunahara
Journal:  Drug Alcohol Depend       Date:  2011-07-19       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.